http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2486300-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1cd8c26e69263bbbd1f8bd74a4019e50 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0647 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M25-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0789 |
| filingDate | 2006-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b8960d1039a6411d7f61445f62fbaa14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a36d012e0f7060675bda13e496cbff51 |
| publicationDate | 2014-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2486300-T3 |
| titleOfInvention | Compositions and methods of repair of vascular lesions |
| abstract | A sterile pharmaceutical composition for use in a method of treating a vascular lesion caused by a myocardial infarction in a subject, the pharmaceutical composition being prepared by a process comprising: (a) sterile purification of a population of nucleated cells comprising cells CD34 + obtained from the subject under sterile conditions to produce enriched CD34 + cells, where the enriched CD34 + cells, which also contain a subpopulation of potent CD34 + / CXCR-4 cells that have CXCR-4-mediated tactical chemo activity, are a product of cells mother chemo tactical hematopoietic (b) confirmation that, for at least 24 hours after obtaining said population of nucleated cells comprising CD34 + cells of the subject, the subpopulation of potent CD34 + / CXCR-4 cells, when analyzed in vitro after passage through a catheter of at least 0.36 mm of diameter: (i) has a tactical chemo activity mediated by CXCR-4; (ii) can form hematopoietic colonies; and (iii) it is at least 70% viable; The pharmaceutical composition comprising: (1) a therapeutic amount of the sterile isolated autologus product of chemo tactical hematopoietic stem cells obtained from the subject and comprising the isolated subpopulation of enriched 25 nucleated cells for CD34 + cells, which also contain a subpopulation of CD34 + / CXCR cells -4+ that have CXCR-4-mediated tactical chemo activity, wherein the therapeutic amount of the chemo-tactical hematopoietic stem cell product comprises at least 0.5 x 106 potent CD34 + / CXCR-4 + cells that have tactical chemo-mediated activity by CXCR-4y is effective in treating vascular lesion; and (2) a stabilizing amount of serum, wherein the stabilizing amount of serum is at least 10% (v / v) and is effective in retaining the tactical chemo activity mediated by CXCR-4 and the activity of forming colonies hematopoietic subpopulation of CD34 + / CXCR-4 + cells; wherein the pharmaceutical composition is formulated for administration to the subject parenterally through a catheter. |
| priorityDate | 2005-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 585.